Financhill
Sell
49

CPRX Quote, Financials, Valuation and Earnings

Last price:
$22.93
Seasonality move :
10.55%
Day range:
$22.85 - $23.35
52-week range:
$13.49 - $24.64
Dividend yield:
0%
P/E ratio:
19.72x
P/S ratio:
6.16x
P/B ratio:
4.20x
Volume:
931.1K
Avg. volume:
1.3M
1-year change:
72.63%
Market cap:
$2.8B
Revenue:
$398.2M
EPS (TTM):
$1.18

Analysts' Opinion

  • Consensus Rating
    Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $32.22, Catalyst Pharmaceuticals has an estimated upside of 38.47% from its current price of $23.27.
  • Price Target Downside
    According to analysts, the lowest downside price target is $28.00 representing -- downside risk from its current price of $23.27.

Fair Value

  • According to the consensus of 7 analysts, Catalyst Pharmaceuticals has 38.47% upside to fair value with a price target of $32.22 per share.

CPRX vs. S&P 500

  • Over the past 5 trading days, Catalyst Pharmaceuticals has underperformed the S&P 500 by -1.45% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Catalyst Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Catalyst Pharmaceuticals has grown year-over-year revenues for 16 quarters straight. In the most recent quarter Catalyst Pharmaceuticals reported revenues of $128.7M.

Earnings Growth

  • Catalyst Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Catalyst Pharmaceuticals reported earnings per share of $0.35.
Enterprise value:
2.3B
EV / Invested capital:
--
Price / LTM sales:
6.16x
EV / EBIT:
13.41x
EV / Revenue:
5.07x
PEG ratio (5yr expected):
0.16x
EV / Free cash flow:
10.52x
Price / Operating cash flow:
12.78x
Enterprise value / EBITDA:
11.04x
Gross Profit (TTM):
$397.5M
Return On Assets:
23.73%
Net Income Margin (TTM):
31.01%
Return On Equity:
27.81%
Return On Invested Capital:
27.81%
Operating Margin:
39.56%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $191.8M $348.4M $460.5M $102.7M $128.7M
Gross Profit $161.2M $301M $397.5M $88.5M $109.4M
Operating Income $83.8M $75.9M $174M -$37.2M $50.9M
EBITDA $84.4M $100.3M $211.4M -$28.6M $60.4M
Diluted EPS $0.61 $0.52 $1.18 -$0.29 $0.35
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $143.3M $192.8M $276.3M $192M $539M
Total Assets $174.9M $223.2M $333.1M $413.2M $772M
Current Liabilities $18.2M $20.6M $44.7M $57.8M $105.4M
Total Liabilities $18.2M $24.6M $63.1M $64.7M $111.1M
Total Equity $156.6M $198.7M $270M $348.5M $660.9M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $95.1M $128M $224.6M $45.1M $72.9M
Cash From Investing $9.2M -$255.2M -$38.8M -$92.8M -$259K
Cash From Financing -$3.1M -$7.9M $135.6M -$10.1M -$6M
Free Cash Flow $95.1M $48.6M $221.8M -$34.2M $72.6M
CPRX
Sector
Market Cap
$2.8B
$43.9M
Price % of 52-Week High
--
48.46%
Dividend Yield
0%
0%
Shareholder Yield
-5.93%
-0.75%
1-Year Price Total Return
72.63%
-34.83%
Beta (5-Year)
0.796
0.748
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $22.99
200-day SMA
Buy
Level $19.45
Bollinger Bands (100)
Buy
Level 20.65 - 22.77
Chaikin Money Flow
Buy
Level 8.4M
20-day SMA
Buy
Level $22.93
Relative Strength Index (RSI14)
Buy
Level 56.46
ADX Line
Buy
Level 19.52
Williams %R
Neutral
Level -46.4407
50-day SMA
Buy
Level $22.16
MACD (12, 26)
Buy
Level 0.25
25-day Aroon Oscillator
Buy
Level 48
On Balance Volume
Neutral
Level 275.2M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (15.3219)
Buy
CA Score (Annual)
Level (2.2711)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-4.5395)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Stock Forecast FAQ

In the current month, CPRX has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPRX average analyst price target in the past 3 months is $32.22.

  • Where Will Catalyst Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Catalyst Pharmaceuticals share price will rise to $32.22 per share over the next 12 months.

  • What Do Analysts Say About Catalyst Pharmaceuticals?

    Analysts are divided on their view about Catalyst Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Catalyst Pharmaceuticals is a Sell and believe this share price will drop from its current level to $28.00.

  • What Is Catalyst Pharmaceuticals's Price Target?

    The price target for Catalyst Pharmaceuticals over the next 1-year time period is forecast to be $32.22 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is CPRX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Catalyst Pharmaceuticals is a Buy. 7 of 7 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of CPRX?

    You can purchase shares of Catalyst Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Catalyst Pharmaceuticals shares.

  • What Is The Catalyst Pharmaceuticals Share Price Today?

    Catalyst Pharmaceuticals was last trading at $22.93 per share. This represents the most recent stock quote for Catalyst Pharmaceuticals. Yesterday, Catalyst Pharmaceuticals closed at $23.27 per share.

  • How To Buy Catalyst Pharmaceuticals Stock Online?

    In order to purchase Catalyst Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How Low Could Tesla Go?
How Low Could Tesla Go?

Shares of EV major Tesla (NASDAQ:TSLA) have been defying gravity…

Is Roper Technologies a Buy, Sell or Hold?
Is Roper Technologies a Buy, Sell or Hold?

At a time when tech stocks are surging, it’s somewhat…

David Bahnsen Dividend Strategy
David Bahnsen Dividend Strategy

David Bahnsen – founder of The Bahnsen Group and author…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 116x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Buy
87
PCOR alert for Feb 18

Procore Technologies [PCOR] is up 0.87% over the past day.

Buy
54
DKNG alert for Feb 18

DraftKings [DKNG] is down 3.74% over the past day.

Sell
30
TWLO alert for Feb 18

Twilio [TWLO] is up 0.34% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock